ABCL News and Press, AbCellera Biologics Inc. From 01/21/21

F-star's antibody engineering platform is seemingly undervalued with comparable companies worth billions of dollars in equity value. The company has an exciting pipeline of early immuno-therapy clinical assets from F-star's recent pivot, 2 years ago, to internal drug development. ...

AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. L...

The Trianni Mouse ® , AbCellera’s technology for generating large databases of human antibodies for drug discovery programs, is granted United States patent AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-genera...

AbCellera Biologics (ABCL) perks 2% premarket after Peter Thiel discloses 5.3% stake or holding of ~14.36M shares of the company.Mr. Thiel serves as a board member of the company and will be involved in reviewing transactions that may result in operational, strategic, financial or g...

Gainers: [[MGNI]] +15.1%. [[SCPS]] +11.4%. [[OCN]] +10.5%. [[CLNE]] +6.9%. [[AMTX]] +4.7%.Losers: [[VYGR]] -11.9%. [[YCBD]] -11.4%. [[SPPI]] -9.4%. [[AHT]] -9.0%. [[ABCL]] -8.7%. For further details see: MGNI, SCPS, YCBD and SPPI among after-hours movers

Study will provide real-world data to evaluate the effectiveness of bamlanivimab in reducing COVID-19 hospitalizations in a high-risk population AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody developed through AbCellera’s collabor...

Expectations are coming in for 2021. Despite the strong recent gains and record valuations, analysts and investors are expecting even more upside based on "the new normal". The IPO market has proven to be an extremely valuable indicator for future returns. Investors are clearly missin...

AbCellera Biologics Inc. (“AbCellera”) (Nasdaq: ABCL), a technology company that aims to become the centralized operating system for next-generation antibody discovery, today announced the closing of its initial public offering of 27,772,500 common shares at a price to the...